In a double-blind, 2-yr study, 16 pubortal patients with growth retardation after RTx were Iroatod with either Norditropin 4 (gr A) or 8 (gr B) IU/m2/day. We studied the effects of growth hormone therapy (GHRx) on: growth (height SDS for ngo (HSDSCA)), bono age (BA), renal graft function (GFR. by I125-Thalamalo, In ml/min/1.73m2) and renal plasma (low (RPF. by I131 -Hippuran, in ml/mtn/1.73m2), bone mineral content (BMC, in (mm Ai eq/mm3)× 103). glucose tolerance tosi (OGTT), plasma IGF-I and -II levels and -binding proteins (IGFBP's). Growth during GHRx was also compared with the 2-year-growth of matched (paired) control patients. Mean (SD) age and BA at start: gr A 15.6(2.6) and 12.6(2.4) yr; gr B 15.7(1.9) and 12.3(2.1) yr.
Results (expressed as mean (SD) or mean):
Growth: HSDSCA improved significantly in both gr A and gr B (P<0.0001), without difference between gr A and B. Compared to the matched control patients our study patients showed a significantly better growth during GHRx: mean (SD) height increment during 2 yr waa 15.3(5.7) cm in GHRx patients versus 6.4(3.8) cm in control patients (P<0.002). BA: Bone maturation was similar for gr A and B and the ΔBA/ΔCA ratio was <1 during GHRx. GFR and RPF: Mean values remained stable during 1 yr of GHRx. However, 5 patients had renal problems during the 2 years; 2 had one episode of acute renal rejection (after 7 and 15 mo, resp.) with restoration of renal function after a course of high dose prednisone, 3 showed chronic vascular rejection with decreasing renal function (after 10, 11, and 21 mo, resp.). OGTT: Glucose levels did not change after 5 mo, but all insuline levels were sign, higher during GHRx (P<0.04); no signs of impaired OGTT. BMC: A continuing and sign, increase in BMC was found (P<0.0001). IGF-1 Mean IGF-1 SDS for BA increased sign, and similarly in gr A (liom −0.11 to 1.82) and gr B (from 0.21 to 1.93)(P<0.0001).
Conclusion: GHRx with 4 IU/m2/day results in a significant and sustained improvement of height patients. Bone maturation was unaffected. The higher GH dose old IU/m2/day had similar results. This strongly indicates that GHRx results in an improved final height.
About this article
Cite this article
Hokken-Koeloqa, A., de Muinck Keizer-Schrama, S., Wolff, E. et al. TWO YEAR RESULTS OF GROWTH HORMONE THERAPY IN ADOLESCENTS WITH SHORT STATURE AFTER RENAL TRANSPLANTATION (RTx). Pediatr Res 33, S67 (1993). https://doi.org/10.1203/00006450-199305001-00385